| TAH Drug Code | ETRE |
|---|---|
| Indications | Chronic obstructive pulmonary disease |
| Dosing | Oral inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day) |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to fluticasone, umeclidinium, vilanterol, or any component of the formulation; severe hypersensitivity to milk proteins |
| Adverse Effects | 1% to 10%: Headache (4%), voice disorder (>=1%), Diarrhea (2%), dysgeusia (2%), constipation (>=1%), oral candidiasis (>=1%), gastroenteritis (1%), Urinary tract infection (>=1%), Influenza (>=1%), Back pain (4%), arthralgia (>=1%), Pneumonia (8%), bronchitis (>=1%), pharyngitis (>=1%), rhinitis (>=1%), sinusitis (>=1%), upper respiratory tract infection (>=1%), cough (1%), oropharyngeal pain (1%) Frequency not defined:Paradoxical bronchospasm <1%, postmarketing, and/or case reports: Anaphylaxis |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |